Dinutuximab | m-entrepreneurship.com

Product Name :
Dinutuximab

Search keywords :
Dinutuximab

drugId :
null

Target Vo:
Disialoganglioside GD2

Target Vo Short Name :
GD2

Moa_Name:
Antibody-dependent cell-mediated cytotoxicity (ADCC) effects

First Approval Country :
United States

First Approval Date Filter:
2015

Origin Company_Name :
National Cancer Institute

Active Company_Name :
National Cancer Institute

Active Indication_Name:
Neuroblastoma

In Active Indication_Name:

Termination Status :

China Termination Status :

Highest Status:
Approved

China Highest Status:

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
CD11b Rabbit mAb Epigenetics
Farletuzumab Anti-infection
DUSP3 Antibody: DUSP3 Antibody is a non-conjugated and Rabbit origined polyclonal antibody about 20 kDa, targeting to DUSP3. It can be used for WB,IHC-F,IHC-P,ICC/IF,FC,IP assays with tag free, in the background of Human, Mouse, Rat.

Author: Betaine hydrochloride

Related Posts